Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Update

<< Previous

Bullboard Posts

Next >>

Comment by Forestviewon Mar 22, 2024 2:52pm

208 Views

Post# 35947759

RE:RE:Update

Wow. Duster, learn the difference between there and their, and loose and lose. So much bad grammar.

And the $23.9M in the bank is in CDN. So, no, it won't cover Nuance. At this point, no request has been made by Nuance to an Ontario court to recognize the financial decision to Nuance, so ATE is operating as per usual.

You see? I actually have facts to support my comments. You add your own comments and thoughts, and if people can navigate your bad grammar they'll see it carries no weight.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages